Dual GIP/GLP-1 receptor agonist. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.
These are long-acting and reach steady state over weeks, so a single day’s timing has little effect. Consistency matters more than the hour.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Weeks 1–4 | 2.5 mg | once weekly | 0.188 mL | 18.8 u | 4 | 10 mg |
| Weeks 5–8 | 5 mg | once weekly | 0.375 mL | 37.5 u | 4 | 20 mg |
| Weeks 9–12 | 7.5 mg | once weekly | 0.563 mL | 56.3 u | 4 | 30 mg |
| Weeks 13–16 | 10 mg | once weekly | 0.75 mL | 75 u | 4 | 40 mg |
| Weeks 17–20 | 12.5 mg | once weekly | 0.938 mL | 93.8 u | 4 | 50 mg |
| Week 21 onward per 4 weeks from here on |
15 mg | once weekly | 1.125 mL | 112.5 u ⚠ | 4 | 60 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Initiation (wk 1–4) | 2.5 mg | once weekly | 0.188 mL | 18.8 u | 8 doses |
| Step 2 | 5 mg | once weekly | 0.375 mL | 37.5 u | 4 doses |
| Step 3 | 7.5 mg | once weekly | 0.563 mL | 56.3 u | 2 doses |
| Step 4 | 10 mg | once weekly | 0.75 mL | 75 u | 2 doses |
| Trial maximum | 15 mg | once weekly | 1.125 mL | 112.5 u ⚠ | 1 doses |
A dual incretin agonist. SURMOUNT-1 established the 5/10/15 mg maintenance arms with a four-week-per-step escalation from 2.5 mg.
Buy TirzepatidePaid affiliate links.
Adding 1.5 mL of bacteriostatic water to a 20 mg vial gives 13.3 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for Tirzepatide run from 2.5 mg to 15 mg, typically once weekly.5 mg to 15 mg, typically once weekly.5 mg to 15 mg, typically once weekly. This site lists each figure with the source it came from rather than giving a single recommended number.
At 13.3 mg/mL, a 2.5 mg dose is 18.8 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 8 doses.
Tirzepatide is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
Yes — Approved-label escalation. The week-by-week table on this page converts each step into the exact amount to draw for your mix.
Need this on one page to print, screenshot or send?
Make a dose card →Side-by-side with the compounds it is most often weighed against — doses, evidence tier and how each is mixed.
Compounds in the same class, or browse the full catalogue.
A small-molecule NNMT inhibitor rather than a true peptide. Research data show reduced adiposity in diet-induced obesity models. D…
Every compound compared in one table: dose range, how often, half-life and evidence tier.